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The disease mechanisms underlying dystrophin-defi-
cient muscular dystrophy are complex, involving not
only muscle membrane fragility, but also dysregu-
lated calcium homeostasis. Specifically, it has been
proposed that calcium channels directly initiate a cas-
cade of pathological events by allowing calcium ions
to enter the cell. The objective of this study was to
investigate the effect of chronically blocking calcium
channels with the aminoglycoside antibiotic strepto-
mycin from onset of disease in the mdx mouse model
of Duchenne muscular dystrophy (DMD).
Treatment in utero onwards delayed onset of dys-
trophic symptoms in the limb muscle of young mdx
mice, but did not prevent degeneration and regen-
eration events occurring later in the disease course.
Long-term treatment had a positive effect on limb
muscle pathology, reduced fibrosis, increased sar-
colemmal stability, and promoted muscle regener-
ation in older mice. However, streptomycin treat-
ment did not show positive effects in diaphragm or
heart muscle, and heart pathology was worsened.
Thus, blocking calcium channels even before disease
onset does not prevent dystrophy, making this an
unlikely treatment for DMD. These findings highlight
the importance of analyzing several time pointsthroughout the life of the treated mice, as well as
analyzing many tissues, to get a complete picture of
treatment efficacy. (Am J Pathol 2011, 178:273–283; DOI:
10.1016/j.ajpath.2010.11.027)
Duchenne muscular dystrophy (DMD) is a devastating
neuromuscular disease affecting 1 in 3500 live male
births. The disease is caused by mutations in the gene
encoding dystrophin, a protein localized to the cytoplas-
mic surface of the sarcolemma. Here, dystrophin is be-
lieved to exert a dual role, both as structural protein
important for membrane integrity and as a scaffolding
protein for ion channels and various signaling pathways.1
Loss of dystrophin results in sarcolemmal instability,
which causes the muscle to undergo continuous cycles
of degeneration and regeneration. The regenerative ca-
pacity is not maintained, however, and this results in
early, progressive weakening of skeletal muscle leading
to loss of ambulation and respiratory failure.2 Dystrophin
is also important in cardiac muscle, and patients fre-
quently develop a dilated cardiomyopathy. One key find-
ing in the pathology of DMD is an elevated intracellular
calcium level,3 and several studies have explored the
potential of pharmacological modulation of calcium influx
as a therapeutic option in this disease.4–8
One of the earliest suggestions that calcium is impor-
tant in DMD was based on cytosolic calcium accumula-
tion in nonnecrotic fibers from DMD patient biopsies not
observed in other dystrophies or myopathies.3 Calcium
accumulation has also been reported in cultures of dys-
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trophic mdx mice.9–11
The simplest explanation for excessive calcium influx
is entry through microtears in the sarcolemma, which are
more abundant in the dystrophic muscle.2 However, cal-
cium influx may also occur through the non-voltage gated
calcium channels, such as the calcium leak channels12
or transient receptor potential (TRP) channel family mem-
bers.13,14 The TRP channels have been proposed to be
implicated in regulated calcium entry of skeletal muscle.
Specifically, members of this family have been sug-
gested to either directly form calcium channels or indi-
rectly regulate calcium influx. It has been proposed that
the nature of these channels could constitute store-oper-
ated calcium entry and/or stretch-activated calcium en-
try.15 Of these, the best characterized in skeletal muscle
are TRPC1 and TRPC3. TRPC1 associates with -syntro-
phin, a protein connected to the dystrophin-glycoprotein
complex (DGC) of the sarcolemma.16 Disruption of the
DGC complex in Duchenne muscular dystrophy could
therefore alter these protein complexes and change the
activity level of TRPC1, causing excessive calcium influx
into dystrophic myofibers. TRPC3 has been shown to
associate with the type 1 ryanodine receptor and other
triadic proteins.17 This channel protein is not involved in
store-operated calcium entry, but it has been suggested
that TRPC3 could form a link between calcium entry and
gene regulation in skeletal muscle via the calcineurin-
nuclear factor of activated T cells signaling pathway.18
Recent studies have suggested a direct relationship
between calcium dysregulation and dystrophin-defi-
ciency. Transgenic overexpression of TRPC3 in mice is
sufficient to induce muscular dystrophy without concom-
itant muscle membrane fragility,19 and inhibition of TRP
channels in dystrophin-deficient mdx mice drastically re-
duces both calcium influx and dystrophy.19,20 Dystrophin
suppresses spontaneous sarcoplasmic reticulum ele-
mentary Ca2 release events, and this inhibitory control,
mediated via mechanosensitive pathways, is disrupted in
mdx mice.21 In addition, myofiber degeneration alone, as
exemplified in the -dystrobrevin null mouse, does not
cause functional muscle defects, and so the develop-
ment of the DMD/mdx dystrophic pathology cannot be
explained solely by membrane fragility.22
The precise molecular nature of the channel or chan-
nels involved is currently unclear, and there is contro-
versy as to whether the non-voltage gated calcium
channels constituted by TRPC family members initiate
the disorder by triggering a cascade of pathological
events.23
Regardless of entry mechanisms, calcium overload in
skeletal muscle fibers results in activation of calcium-
dependent proteolytic enzymes (calpains), which cause
necrosis and degeneration24,25 and which even degrade
the compensatory protein utrophin.26 In addition, calcium
overload has a detrimental impact on mitochondrial
structure and function, resulting in apoptosis, decreased
activity and mislocalization.27 This chronic damage even-
tually exhausts the normal muscle repair mechanisms
mediated by the resident satellite cells28 and leads to
end-stage disease.DMD fetuses display both ultrastructural disturbances
and increased calcium content of the skeletal mus-
cles.29,30 In the mdx mouse model of DMD, the dystro-
phic process also begins early in embryonic develop-
ment and includes stem cell loss and structural muscle
changes.31 Knockdown of dystrophin in adult mice does
not cause any evident dystrophy,32 indicating that the
disease has a developmental onset. Based on the in-
volvement of calcium homeostasis and stretch-activated
calcium channels in dystrophic pathology and the em-
bryonic/fetal prepathological disturbances, the objective
of the present study was to test whether blocking calcium
influx from embryonic development can prevent initiation
of pathology or alleviate the pathology to a greater extent
than has been shown previously using short-term treat-
ment regimes.5,6,8 We started our treatment regimen
when female mice were fertilized, as detected by a vag-
inal plug, and continued the treatment for up to 6 months
after birth. The strategy adopted was to nonspecifically
block calcium channels33,34 by treating our mice with the
aminoglycoside antibiotic streptomycin in the drinking
water, as previously described.8
Long-term treatment starting in utero of mdx mice did
alleviate limb muscle pathology, but had adverse effects
on cardiac and diaphragm tissue. This discordant tissue
effectiveness could relate to variations in pathological
severity of the analyzed tissues and suggests that the
pathology is more complex than previously believed. Any
preclinical drug trial conducted in the mdx mouse should
therefore include analysis of a range of time points and a
variety of tissues. Specifically, because DMD patients
succumb to respiratory and cardiac failure, cardiac tis-
sue and diaphragm should be included in any preclinical
studies on treatments for DMD.
Materials and Methods
Animal Experiments
C57BL/10-mdx (mdx) and C57BL/10 (BL/10) mouse
breeding pairs were plug-checked every day. When a
vaginal plug was observed, the mother was treated with
streptomycin (Sigma-Aldrich, St. Louis, MO) in the drink-
ing water (4 g/L); the bottles were changed twice per
week. Streptomycin is known to cross the placental mem-
brane.35 On giving birth, the mother was continued on
streptomycin in the water; the pups, when weaned, were
continued on the same dose in their drinking water. The
treated pups were analyzed after 6 weeks (n  3–5), 10
weeks (n  4–6), and 6 months (n  3–5 for histology
and Western blots, n  5–11 for magnetic resonance
imaging [MRI]) of continued postnatal treatment. Male
mice were used for MRI scanning and Evans Blue dye
uptake, because extensive control data were available in
male mice for these measurements and to be able to
correlate heart membrane damage with heart function. To
minimize animal usage, females were used for all other
analyses.
Toxicity of streptomycin was tested on mouse urine
samples. Samples were collected by scruffing the mice
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samples were then analyzed using a dipstick test for
proteinuria and ketonuria (Bayer Multistix GP diagnostic
strips; MediSupplies, Dorset, UK). Urine samples were
additionally analyzed for proteinuria using a bicincho-
ninic acid kit for protein determination (Sigma-Aldrich).
All animal experiments were in accordance with the
Home Office Guidelines, United Kingdom, and were per-
formed under license no. PPL60/3445.
Human Biopsy Material
Human fetal tissue was obtained during autopsy of
aborted fetuses aged 13 weeks (DMD) and 15 weeks
(control). Diagnosis of DMD was made on the basis of
DNA analysis. Biopsies were obtained and used ac-
cording to the guidelines of and with permission from
the Regional Ethics Committee for Southern Denmark
#15879.
Histology
Diaphragm, tibialis anterior (TA), and heart ventricular
tissue was harvested and processed for histology by
snap-freezing in isopentane cooled in liquid nitrogen and
stored at 80°C. Cryosections were cut (10 m thick) and
were stained with hematoxylin and eosin (H&E) for general
pathology, Sirius Red for detecting fibrosis, and Alizarin
Red for detecting large accumulations of calcium/necrotic
fibers, using standard procedures.
Muscle regeneration was assessed by counting the
number of myofibers with centrally localized nuclei. Two
random areas covering a total of 300–500 fibers were
counted from 3 to 5 animals at 6 weeks and at 10 weeks
of age. Sections were analyzed and photographed using
a Zeiss Axioplan microscope.
Immunohistochemistry/Immunofluorescence
The 10-m cryosections were fixed with 4% paraformal-
dehyde in phosphate-buffered saline (PBS) for 15 min-
utes. Sections were washed and endogenous peroxidase
blocked in 1.5% H2O2/Tris-buffered saline (TBS) followed
by washing and blocking of endogenous biotin using
avidin-biotin (DakoCytomation, Glostrup, Denmark). This
was followed by three washes in TBS-Tween20 (TBS-T);
finally, the slides were blocked with 4% bovine serum albu-
min (BSA)/TBS. Primary antibodies used were mouse-anti-
human desmin 1:25 (DakoCytomation, D33) labeled with
biotinylated-F(ab=) fragments using the ARK research kit
(DakoCytomation) as previously described,36 rat-anti-
CD45 1:50 (MCA1388; AbD Serotec, Kidlington, UK) as
previously described,37 and rabbit-anti-TRPC3 (Alomone
Labs, Jerusalem, Israel) 1:500. TRPC3 was detected us-
ing donkey anti-rabbit Alexa594 1:200 (Invitrogen, Carls-
bad, CA) and mounted using Vectashield with 4=,6-dia-
midino-2-phenylindole (DAPI) for detection of nuclei
(Vector Laboratories, Burlingame, CA). CD45 was de-
tected using rabbit anti-rat biotinylated antibody 1:200,
followed by streptavidin-horseradish peroxidase and de-
velopment using the DAB kit (Vector Laboratories), nu-clei were counterstained in hematoxylin and slides were
mounted with Aquatex (Merck Biosciences, Darmstadt,
Germany). Desmin was detected similarly to CD45, ex-
cept for omitting the secondary antibody step.
Desmin- and CD45-positive areas marking regenerat-
ing and inflamed areas, respectively, were semiquanti-
fied using a scoring system as follows: no staining  0,
weak staining with few cells/structures/areas  1, mod-
erate expression with small number of areas/structures
2, strong expression, vast areas, many cells/structures 
3, and massive expression all over the tissue  4. Sec-
tions were analyzed and photographed using a Zeiss
Axioplan microscope.
Western Blotting
Two different preparations were used, either crude mus-
cle extracts, used for the 6-week time point (10 mmol/L
Tris-HCl, 1% Triton X-100, 0.5 L/ml phenylmethanesul-
fonylfluoride [Roche], and protease inhibitor cocktail
[Roche]) or the total membrane fraction isolated using a
plasma membrane protein extraction kit (BioVision,
Mountain View, CA), used for the 10-week and 6-month
time points. Only total membrane fractions were ex-
tracted and analyzed using the kit.
The preparations (200–500 ng total membrane fraction
or 25 g crude extracts) were mixed in a 30-L volume
containing loading buffer (Invitrogen), reducing agent
(Invitrogen) and water. Samples were incubated at 95–
100°C for 5 minutes, briefly spun down and loaded onto
Bis-Tris 4–12% gradient gels (Invitrogen). Gels were run
for 45 minutes at 200V. Proteins were transferred to a
PVDF membrane (GE Healthcare, Waukesha, WI) for 1
hour at 350 mA. Loading and transfer were analyzed
using Ponceau staining (Sigma-Aldrich). Membranes
were washed in TBS-T and blocked for 1 hour at room
temperature or overnight at 4°C in TBS-T with 5% nonfat
milk. Primary antibodies were incubated overnight at 4°C
except for neural cell adhesion molecule (NCAM), which
was incubated for 2 hours at room temperature, in the
following concentrations: rabbit-anti-TRPC3 1:4000
(Sigma-Aldrich), rabbit-anti-TRPC3 1:5000 (Alomone
Labs), mouse-anti--dystroglycan 1:50 (43DAG; Novo-
castra, Newcastle upon Tyne), mouse anti-dystrophin
1:100 (DY8; Novocastra), and rabbit anti-NCAM 1:8000
(Millipore Bioscience Research Reagents, Temecula,
CA). Membranes were washed three times for 10 minutes
with TBS-T and incubated with secondary goat anti-
mouse-horseradish peroxidase (HRP) 1:5000 or goat an-
ti-rabbit-HRP 1:5000 for 1 hour at room temperature. Im-
munoreactive bands were detected using an enhanced
chemiluminescence kit (GE Healthcare).
Semiquantification of Western blots (TRPC3 and
-dystroglycan) was performed using Adobe Photoshop,
CS5, and standardized to the ponceau stain band of
approximately 80–90 kDa.
Evans Blue Dye Uptake
Evans Blue dye (0.25 mg per 10 g body weight in PBS)
was injected intraperitoneally 16–24 hours before MRI.
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dissected out for histological analysis. Atrial tissue was
removed from the hearts, which were then washed in PBS
and snap-frozen in isopentane cooled in liquid nitrogen
along with TA and diaphragm muscle. Transverse sec-
tions (8–10 m thick) were cut and incubated in ice-cold
acetone at 20°C for 10 minutes, washed three times for
10 minutes with PBS, and mounted with Vectashield
mounting medium (Vector Laboratories).
All sections were examined and photographed using a
Zeiss Axioplan fluorescence microscope. Evans Blue dye
staining shows a bright red emission. An Evans Blue dye
uptake score was obtained as follows, performed blinded
by two individual observers who scored all sections in
parallel and decided on an agreed scoring: 0, no uptake;
1, fewer than three areas of uptake; 2, greater than three
areas of uptake; 3, greater than three areas of uptake and
at least one area 100 m in diameter; 4, greater than
three areas of uptake and with all areas showing massive
uptake of 100 m in diameter.
Magnetic Resonance Imaging
Mice were anesthetized using 5% isoflurane, and anesthe-
sia was maintained at 1.5% in oxygen with a flow rate of 0.5
L/min. The tail vein was cannulated and the mouse was
placed on a sled with cutaneous ECG electrodes, respira-
tion pillow, and temperature detector (Dazai Research In-
struments, Toronto, ON) and connected to SA instrument
monitoring equipment (SA Instruments, Stony Brook, NY).
Mice were scanned in a 39-mm-diameter quadrature
birdcage volume coil (Rapid Biomedical, Rimpar,
Germany).
Images were acquired on a horizontal 7-T microimag-
ing system (Varian; Agilent Technologies, Santa Clara,
CA) equipped with a 12-cm microimaging gradient insert
(maximum gradient, 40 mT/m).
After power calibration and global shimming, a series
of four pilot transverse images were acquired over the
heart. Single-slice coronal and sagittal images were then
obtained to view the apex and mitral valve planes. These
images were used to plan for the true short-axis plane.
Up to 10 contiguous short-axis slices were acquired to
cover the entire left ventricle using a spoiled gradient-echo
cine sequence: TR  5 ms, TE  1.42 ms, flip angle  15
degrees, field of view  30  30 mm, data matrix  128 
128, slice thickness  1 mm. Images were ECG-triggeredto the R-wave with a cine delay of 15 ms, and typically 30
phases were acquired distributed through the cardiac cy-
cle. Images were zero-filled to a matrix size of 256  256.
Scans were analyzed using the freely available analysis
software program Segment v1.8 (http://segment.heiberg.
se)38 to give left ventricular functional parameters.
Statistics
Student’s unpaired two-tailed t-test with an -value of
0.05 was performed using GraphPad Prism 5 (GraphPad,
La Jolla, CA). Cardiac MRI data were compared using
one-way analysis of variance.
Results
Prepathological Calcium Accumulation Indicates
Involvement of Calcium Dysregulation in
DMD/mdx Pathogenesis
Skeletal muscle from DMD fetuses displays ultrastruc-
tural changes including degenerative fibers,30 suggest-
ing that onset of DMD occurs already in utero. It is unclear
what comparison can be made between late gestation in
humans and the early days after birth in the mouse;
however, the onset of pathology is later in the mdx
mouse, beginning about 3 weeks postpartum. We there-
fore wanted to analyze if we could detect calcium distur-
bances in relation to this early onset of DMD pathology
and also extend the analysis to include detection of the
earliest time point for accumulation of calcium in the mdx
mouse model of DMD. This would prove our hypothesis
that calcium accumulation immediately precedes the on-
set of histologically defined pathology.
We analyzed human DMD (13 weeks) and control (15
weeks) fetal skeletal muscle biopsies in comparison with
mdx and C57/BL10 control mouse (BL/10) embryos at
embryonic age 9.5, 11.5, and 18.5 days (data not shown)
and mouse postnatal muscle at 12–13 days (data not
shown) and 3 weeks old (Figure 1, A and B). We de-
tected calcium accumulation in the human DMD fetal
biopsy (Figure 1A), compared with the control fetal
muscle. We did not detect any calcium accumulation in
mdx muscles until age of known onset, which is around
3 weeks postnatally (Figure 1B).39 Centrally located
nuclei indicative of ongoing muscle development were
Figure 1. Pre-onset accumulation of calcium in
dystrophin-deficient skeletal muscle suggests
early implication of calcium dysregulation in
DMD pathology. A: Calcium uptake (Alizarin
Red positive fibers, red) in skeletal muscle from
a fetus (13 weeks old) with DMD, compared
with skeletal muscle from a control fetus (15
weeks old), which shows no uptake. B: Calcium
uptake in tibialis anterior (TA) of C57/BL10-mdx
(mdx) mice was not detectable until postnatal
week 3. Central nuclei were detectable in both
C57/BL10 control (BL/10) and mdx skeletal mus-
cle (TA), confirming ongoing muscle develop-
ment at this stage. Insets correspond to the
higher-magnification image to the left. Scale
bars  100 m.
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whereas in the dystrophic muscle an inflammatory in-
filtrate in the area positive for calcium uptake was
observed as well (Figure 1B, H&E stain).
Short-Term Treatment with Streptomycin
Improves mdx Limb Skeletal Muscle Pathology
Streptomycin treatment was started as soon as female
mice were plugged, to expose the offspring in utero. At 6
weeks of age, an improvement in pathology in the TA
muscle was detectable (Figure 2), consistent with previ-
ous short-term streptomycin treatments of mdx mice.6,8 A
significant drop in the percentage of centrally localized
nuclei (Figure 2A) (P  0.05) and less inflammation
(CD45 semiquantification 1.6  0.55 in mdx S vs. 2.7 
0.57 in mdx C, P  0.05) was observed in the treated
animals (Figure 2D).
Active regeneration was observed as desmin-positive
myotubes in dystrophic mice, regardless of treatment,
suggesting that streptomycin could not completely pre-
vent onset and progression of pathology. This was sup-
ported by the presence of necrotic foci regardless of
treatment as judged by Alizarin Red staining (Figure 2D).
TRPC3 expression overall was very patchy, even in
C57BL/10 control muscle (BL/10 C), with localization to the
membrane and cytosol without any obvious difference in
expression level. However, Western blot confirmed that
6-week-old mdx C mice showed increased expression of
TRPC3, compared with BL/10 C (Figure 2B).
Intriguingly, TRPC3 was detected in the nuclei of newly
regenerating fibers (Figure 2D). This staining pattern was
generally not observed in nuclei of BL/10 C muscle, un-
injured mdx muscle, or nuclei in heart transverse sections
from both mdx and BL/10 mice. A negative control stain-
ing, omitting primary antibody, showed no nuclear stain-
ing (Figure 2D, inset); staining was abolished by compe-
tition with the appropriate peptide (data not shown), and
the antibody specificity has been verified previously.40
An identical staining pattern was observed with an alter-
native antibody raised against TRPC3 (data not shown).
The increased expression of TRPC3 observed in mdx
mouse muscle (Figure 2B) could therefore be a conse-
quence of ongoing regeneration, rather than a primary
pathological feature.
Streptomycin is an aminoglycoside, and some amin-
oglycosides read through premature stop codons.41 Be-
cause the mdx mutation is a stop codon in exon 23,42 it
appeared possible that read-through had occurred and
caused any improvement seen in our study. However, the
improvement observed at 6 weeks of age was not caused
by read-through of the mdx stop-codon mutation, be-
cause dystrophin protein was not detected (Figure 2C).
Continued Treatment up to 10 Weeks of Age
Failed to Prevent Progressive Pathology in
Limb, Heart, and Diaphragm Muscle
Although the 6-week time-point data were supportive for
unspecific calcium channel blockade as a potential treat-Figure 2. Treatment with streptomycin improves central nuclei counts and
pathology in TA of mdx mice in utero and 6 weeks postnatal. A: Central
nuclei counts (% CN) in C57/BL10 (BL/10 C), C57/BL10-mdx control (mdx
C), and streptomycin-treated (mdx S) mice. Data are expressed as means 
SD of 3–5 mice. There is a statistically significant reduction in %CN in mdx S,
compared with mdx C (*P  0.05). B:Western blot detection of TRPC3 (mol.
wt. 97 kDa) in crude muscle extracts. Ponceau stain band mol. wt. 80–90
kDa was used as standard and loading control. We detected significantly
increased TRPC3 protein in mdx skeletal muscle, compared with BL/10
control (**P  0.01). C: Western blot results of dystrophin (mol. wt. 427
kDa) expression in TA from 6-week-old mdx S, mdx C, and BL/10 C. There
is no dystrophin protein expressed in mdx mice, regardless of treatment,
indicating that read-through of the dystrophin stop codon mutation has not
occurred. Representative results from two mice per group are shown. D:
Representative images of histological examination of BL/10 C, mdx C, and
mdx S mice. The H&E staining shows general histology; CD45 detects all
lymphocytes and is a marker of inflammation; and desmin is expressed by
regenerating and newly forming fibers and is a marker for immature fibers
and ongoing regeneration. Overall histology points toward less necrosis and
inflammation in mdx S, compared with mdx C. TRPC3 protein expression
is detectable in membrane, cytoplasm, and nuclei of both mdx C and mdx
S mice and the expression appears to be increased in newly formed
myotubes. This TRPC3 expression pattern in mdx control and treated
mice, compared with BL/10 C, correlates with the increased expression
seen on Western blots (B). Inset: Negative control image for TRPC3
immunohistochemical staining for BL/10 C. Nuclei are counterstained
with DAPI in blue. Alizarin Red (ARed) staining shows necrotic foci with
calcium accumulations and there is no detectable difference between mdx
C and mdx S. Scale bar  50 m.
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the treatment up to the age of 10 weeks did not maintain
the improvement. We no longer observed a significant
difference in the number of central nuclei (Figure 3A)
between treated and untreated dystrophic mice. On his-
tological examination of limb and diaphragm muscles,
there were no observable differences in overall histology
(Figure 3, C and G). Semiquantitative analysis of the
Figure 3. Continued treatment with streptomycin up to 10 weeks of age
does not prevent pathological progression in TA (A–E), heart (F), and dia-
phragm (G). A: Central nuclei counts (% CN) in BL/10 C, mdx C, BL/10 S
(C57BL/10 treated), and mdx S mice show no difference between mdx C and
mdx S (P  0.05) at 10 weeks of age. Data are expressed as means  SD of
3–6 mice. B: Western blot detection of dystrophin (427 kDa) and neural
cell adhesion molecule (NCAM; 160 kDa breakdown product) in total
membrane fractions from TA muscles. Blots not run on same gels or reor-
ganized from different parts of the same gels are all separated by a black line.
C: Representative images of histological examination of TA muscles from
mdx C and mdx S. Top to bottom: H&E, CD45, desmin, TRPC3, and Alizarin
Red staining. Overall there appears to be no difference in pathology between
mdx C and mdx S. Scale bar  100 m. D: TRPC3 protein expression is
significantly increased in mdx C, compared with BL/10 C (*P  0.05). Based
on Western blot detection of TRPC3 (97 kDa). Ponceau stain band mol. wt.
80–90 kDa was used as standard and loading control. E: -dystroglycan
protein expression is significantly decreased in mdx C, compared with BL/10
C (*P 0.05). Based on Western blot detection of -dystroglycan (43 kDa).
Ponceau stain band Mw 80–90 kDa was used as standard and loading
control. F: Top panel: Quantification of fibrosis in 10-week-old mdx C and
mdx S hearts. Data are actual measurements, expressed as mean SD of 3–4
mice. Bottom panel: Increased fibrosis (red) in heart muscle from mdx S,
compared with mdx C, detected using Sirius Red. Scale bar  100 m. G:
Histological analysis of diaphragm muscle from 10-week-old mice of each
group using H&E shows no obvious difference in pathology between mdx C
and mdx S. Scale bar  100 m.immunohistochemistry could not detect any significantdifference in inflammation (CD45 in TA: mdx C 2  0.04
vs. mdx S 2.2  0.4, P  0.05; CD45 in diaphragm: mdx
C 2.25 0.5 vs. mdx S 3.2 0.2, P 0.05) or in ongoing
regeneration (desmin in TA: mdx C 1  0.4 vs. mdx S 1.2
 0.2, P  0.05; desmin in diaphragm: mdx C 3.25  0.2
vs. mdx S 2.8 0.2, P 0.05). The ongoing regeneration
in TA was confirmed by high expression levels of
NCAM43 (Figure 3B). Necrotic foci detected by Alizarin
Red staining were equally present in both control and
treated mdx mice.
Absence of dystrophin in both control and treated mdx
mice confirmed that there was no read-through activity at
10 weeks of age (Figure 3B).
TRPC3 expression showed the same overall features
as the 6-week time point, with patchy expression and
presence of TRPC3 protein in the nuclei of regenerating
fibers as well (Figure 3C). Semiquantification of TRPC3
Western blot (Figure 3D) showed that TRPC3 protein was
increased in mdx C (1.62  0.24) vs. BL/10 C (0.89 
0.59) (P  0.05). After treatment with streptomycin,
TRPC3 protein expression level did not change in BL/10
mice (0.97  0.31, P  0.05 BL/10 C vs. BL/10 S), but
appeared to decrease in treated mdx mice (0.95 0.45);
however, this could not be confirmed by semiquantifica-
tion (P  0.05, mdx C vs. mdx S).
Semiquantification of -dystroglycan protein expression
in mdx C (1.36 0.31) vs. BL/10 C (2.46 0.31) (P 0.05)
showed down-regulation in dystrophic mice, as expected
(Figure 3E).44 Expression of -dystroglycan did not appear
to change in BL/10 mice after streptomycin treatment (Bl/10
S 1.90  0.19, P  0.05 vs. BL/10 C). In dystrophic mice,
treatment appeared to increase expression level of -dys-
troglycan, but this could not be confirmed statistically (mdx
S 1.90  0.47, P  0.05 vs. mdx C).
We also examined heart muscle pathology at this time
point, using Sirius Red staining for fibrosis followed by
semiquantitative analysis of the histological images (Fig-
ure 3F). There was a trend toward increased fibrosis in
the hearts of treated mdx mice (mdx S % fibrosis 0.68 
0.47), compared with controls (mdx C % fibrosis 0.14 
0.071), but this did not reach statistical significance (P 
0.05). No fibrosis was detected in hearts from BL/10 C or
BL/10 S mice (data not shown).
Long-Term Treatment Alleviates Limb Muscle
Pathology but Cardiac and Diaphragm
Pathology Is Worsened
The final time point to be analyzed was after continued
treatment until the age of 6 months. To examine whether
long-term treatment with streptomycin induced kidney
damage, total protein urine content was analyzed. All
mice had similar levels (0.3 g/L). In addition, we analyzed
the urine samples for ketones, and all were negative.
Histological analysis of kidneys and livers in H&E-stained
sections from paraffin-embedded tissue did not demon-
strate histological changes in any of the groups (data not
shown), suggesting that there were no adverse side ef-
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forming a simple hearing test in which fingers were
snapped behind the mice and the Preyer reflex ob-
served.45 All groups behaved similarly.
On routine histological examination of H&E stainings,
an improvement in limb muscle pathology was observ-
able in treated mdx mice. Specifically, large areas with
ongoing necrosis were still detectable in mdx C (Figure
4A), whereas in mdx S mice (Figure 4A) the only sign of
pathology was occasional small repaired areas with myo-
tubes and centrally located nuclei without any necrosis.
However, in both treated and control mdx mice 95% of
the limb muscle fibers had centrally located nuclei (data
not shown), suggesting that most muscle fibers had gone
through at least one round of degeneration and regener-
ation. Diaphragm muscles presented with severe necrosis
combined with large areas of fibrosis and regenerative fi-
bers, suggesting that streptomycin treatment had no effect
in this more severely affected tissue46 (Figure 4A). These
histological observations were confirmed by Sirius Red
staining for fibrosis (Figure 4B) showing that TA muscles
from treated mdx mice (Figure 4B) appeared to have re-
duced thickening of the endo- and perimysium, compared
with control mice (Figure 4B), whereas there was no obvi-
ous difference in the diaphragm muscles (Figure 4B).
We also examined the effect on cardiac pathology.
Fibrosis was observed (Figure 4C) in hearts from both
treated and control mdx mice, and on quantification the
percentage of fibrosis was significantly increased in
treated hearts (mdx C 3.27 0.34 vs. mdx S 4.28 0.28,
P  0.05) (Figure 4D). In addition, there was severe
necrosis in the treated hearts, which was not observed in
control dystrophic hearts (Figure 4C).Magnetic resonance imaging scanning of treated and
control BL/10 and mdx mice did not reveal any difference
in left ventricular function between dystrophic mice, re-
gardless of treatment, and both groups demonstrated
well-compensated function, as previously reported using
the conductance catheter technique.47 Cardiac pathol-
ogy in dystrophic mice has previously been character-
ized by increased left ventricular mass.48 Magnetic res-
onance imaging confirmed that there was a significant
increase in left ventricular mass in mdx C, compared with
BL/10 C and that this was not improved in mdx S mice
(Figure 4D). Overviews from the heart scans are pre-
sented in Figure 4D (long-axis and short-axis images
taken from a healthy BL/10 C mouse).
No damage was observed in TA, diaphragm, or heart
from BL/10 S, compared with controls, as judged from
histological analysis (data not shown).
Membrane Damage Is Reduced in Limb Muscle
after Long-Term Treatment with No Effect on
Diaphragm and Cardiac Muscle
Membrane damage, as detected by Evans Blue dye up-
take, was significantly reduced in TA muscle after 6
months treatment in dystrophic mice (Figure 5, A and B)
(P  0.01), compared with controls; however, there was
no detectable difference in membrane damage in dia-
phragm and cardiac muscle (Figure 5, A and B).
Using Western blotting analysis of both heart tissue
and TA, we confirmed that there was still no detectable
read-through activity in the dystrophin gene by the ami-
noglycoside that could account for the positive effect
Figure 4. Improvement of limb muscle pathology
combined with aggravation of cardiac pathology af-
ter continued treatment for 6 months. A: Representa-
tive images for H&E histological examination of TA
and diaphragm from mdx C and mdx S. There is an
overall improvement in limb muscle pathology in
6-month-old mdx S mice, but no obvious difference
in diaphragm pathology, compared with mdx C. B:
Sirius Red staining detecting fibrosis (red) in TA and
diaphragm from 6-month-oldmdx C andmdx S con-
firms the H&E histological findings of improvement
in limbmuscle pathology observed as reduced fibro-
sis. Nodifference in diaphragm fibrosis betweenmdx
C and mdx S. C: Examination of fibrosis in 6-month-
old heart muscle of mdx C and mdx S and presence
of necrotic foci (Alizarin Red) in 6-month-old heart
muscle of mdx C andmdx Smice. There is increased
fibrosis combined with necrosis in mdx S hearts,
comparedwith controls, showing aworsening of the
pathology.D: Toppanels: Representative images of
a heart MRI scan from a 6-month-old C57BL/10 con-
trol mouse showing both short-axis and long-axis
views. Bottom panels: Quantification of fibrosis in
6-month-old hearts shows a statistically significant in-
crease in fibrosis in mdx S hearts, compared with
mdx C. Data are actual measurements from 6–8
mice, expressed as means  SD. *P  0.05. Left
ventricular mass (LVM) measurements normalized to
body weight performed using MRI scanning and
analysis using the software program Segment (as de-
scribed under Materials and Methods). There were
significant differences in LVM when comparing
BL/10 to all other groups using one-way analysis of
variance analysis (P  0.0001), although streptomy-
cin had no significant effects on LVM. Data are ex-
pressed as means of 5–11 mice  SD.streptomycin treatment (Figure 5C). There was increased
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compared with all other groups, suggesting that there
was increased muscle regeneration or stalled myofiber
maturation in these mice at this time point (Figure 5D).
Both treated and control mdx mice appeared to have a
reduced expression of TRPC3 compared with the BL/10
groups. However, TRPC3 protein expression level ap-
peared to be higher in treated mdx mice, compared with
controls, again indicative of TRPC3 protein being actively
transcribed and expressed by regenerating fibers, be-
cause increased NCAM was detected in the treated mdx
mice as well (Figure 5D). Finally, there appeared to be
increased expression of -dystroglycan in the treated
dystrophic mice, which appeared to have normalized
Figure 5. Membrane fragility is improved in limb muscle of mdx mice after
6 months treatment with streptomycin, but heart and diaphragm pathology is
not improved. A: Representative images of Evans Blue Dye (EBD) uptake in
TA, diaphragm, and heart tissues harvested from the same mouse for mdx C
and mdx S, respectively. There is great variability in uptake both in different
tissues examined from the same mouse and in the same tissue types exam-
ined from different mice. B: Quantification of EBD uptake in TA, diaphragm,
and heart tissue from mdx C and mdx S. Data are from 4–5 mice, expressed
as means  SD. **P  0.01 for EBD uptake in TA in mdx C vs. mdx S. There
were no significant differences in diaphragm and heart tissue, which both
show a highly variable uptake pattern. C: Western blot detection of dystro-
phin (427 kDa) expression in TA and heart muscle from 6-month-old BL/10
C, mdx C, BL/10 S, and mdx S mice. There is no dystrophin protein expressed
in TA or heart muscle from mdx mice regardless of treatment, indicating that
read-through of the dystrophin stop codon mutation has not occurred even
after 6 months of treatment. Representative results from two mice per group
are shown. D: Western blot detection of NCAM (160 kDa), TRPC3 (97
kDa), and -dystroglycan (43 kDa) protein expression in total membrane
fractions from 6-month-old TA muscle from BL/10 C, mdx C, BL/10 S, and
mdx S. Representative results from two mice per group are shown. Ponceau
staining was used as loading control (protein band of80–90 kDa is shown).toward wild-type levels (Figure 5D).Discussion
The understanding of the pathophysiological mecha-
nisms of DMD has become increasingly complex since
the discovery of the underlying genetic defect,49 and still
no cure exists, more than 20 years later. The only avail-
able treatment to ameliorate skeletal muscle weakness
and wasting is glucocorticoids, but this treatment is as-
sociated with potentially severe side-effects, such as
weight gain and osteoporosis.50 It is therefore essential to
continue testing new treatment strategies.
In the present study, we focused our attention on the
hypothesis that calcium dysregulation could be a primary
event in developmental onset of pathology, based on
several recent studies suggesting that calcium channel
proteins might be involved in disease initiation.13,16,19
Our confirmation of early calcium accumulation in DMD
fetal muscle is important for determination of the patho-
physiological mechanisms, and also for defining the op-
timal time-point for initiation of treatment. This is sup-
ported by a previous study in which transgenic
expression of utrophin in mdx mice from developmental
onset reduced dystrophic pathology to a much greater
extent than expression initiated at birth or postnatally,23
indicating that it is important when a therapeutic interven-
tion is started. Based on the defects observed before
histopathological onset in DMD/mdx, we wanted to ana-
lyze whether blocking calcium channels in the dystrophic
mice from embryonic development and throughout adult-
hood could prevent pathological onset or progression.
We observed a complex pathological pattern in which
treatment outcome varied with age, ongoing disease pro-
gression, and tissue. Long-term treatment for 6 months,
which may be the most relevant time point for comparison
with the human condition, resulted in improved limb mus-
cle pathology, but worsened cardiac pathology.
Previous studies have suggested a direct role for the
TRP channel proteins in DMD pathology, and recent data
show that transgenic expression of TRPC3 could induce
a dystrophic pathology without concomitant membrane
fragility.19 During this study we therefore recorded ex-
pression and localization pattern of TRPC3 to see if cal-
cium channel blockade induced changes in expression
pattern and whether this correlated with pathology.
TRPC3 expression was increased in mdx mouse mus-
cle of young mice, but appeared to be reduced in older
mice. Expression appeared stronger and localized both
to the membrane and to cytoplasm and nuclei in regen-
erating fibers, compared with uninjured fibers in younger
mice. The intracellular localization is in agreement with a
study showing colocalization of TRPC3 with GLUT4 in the
transverse tubular system.51 The nuclear localization of
TRPC3 is unexplained, but has also been observed in a
recent study.14 and regulated expression of TRPC3 dur-
ing myotube development in vitro17 supports a correlation
between TRPC3 expression and regeneration.
In the present study, localization of TRPC3 to the nuclei
was observed only in regenerating myofibers of skeletal
muscle; we did not detect this nuclear pattern in unin-
jured skeletal muscle or ventricular myocytes (data not
shown). Our observations are in accordance with a re-
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lated disks and intracellular membranes of ventricular
myocytes was shown.52 Because the function of TRPC3
appears to be different in adult muscle versus developing
muscle,14 our observations lead us to propose that the
up-regulation of TRPC3 protein in young dystrophic
mouse muscle could relate to ongoing regeneration.
Nonetheless, dysregulated TRPC3 in early development
caused by lack of dystrophin could also be a specific
pathological feature. This needs to be investigated fur-
ther in specific models of muscle regeneration.36,37
TRPC1 may form part of the putative calcium channels
implicated in DMD pathology, because inactivating
TRPC1 expression in mdx muscle fibers abrogated a
calcium leak channel13 and because TRPC1 is directly
associated with the dystrophin-glycoprotein complex.16
Specifically it has been proposed that the TRPC1 protein
might constitute a stretch-activated calcium channel.53
However, recent observations in TRPC1 knockout mice
suggest that this channel is not mechanosensitive, nor is
it involved in store-operated calcium entry54; thus, the
actual gating mechanism remains unknown. Nonethe-
less, TRPC1 appears to be indispensible for muscle ac-
tivity, and TRPC1 knockout mice undergo muscle fatigue
much faster than control mice.54 The role of TRPC3 and
TRPC1 in relation to DMD remains elusive.
In the present study, reducing calcium influx in limb
muscle via blockade of the calcium channels resulted in
reduced signs of fiber damage in 6-week-old mice, in
accordance with a previous study.8 The number of cen-
tral nuclei then increased in both treated and untreated
mdx mice with continued treatment and was no longer
significantly different at 10 weeks of age. This suggests
that there is an early delay in pathological progression
after treatment.
Streptomycin has also been shown to have a directly
harmful effect on mitochondrial ribosomes55; thus, cumu-
lative damage on mitochondria may present later as ac-
celerated degeneration (observed here as increased
numbers of centrally localized nuclei). Another explana-
tion for the transitory effect might be that the beneficial
treatment effect diminishes over time.56
Our study on limb muscle pathology, however, actually
indicated that blocking calcium influx results in ongoing
regeneration and less necrosis in the muscles of older
mdx mice, thus supporting the suggested mechanism of
more efficient repair. In this context it is important to
notice that the presence of centrally located nuclei indi-
cates only that regeneration has occurred, not how many
times each individual myofiber has undergone a round of
necrosis followed by regeneration. It can therefore be
speculated that, if the muscles have undergone fewer
cycles of degeneration and regeneration, the satellite cell
pool would benefit, because it will not become ex-
hausted. The satellite cells will then still be available for
repair of muscle fibers damaged by membrane fragility-
induced events. This would result in the observed pattern
of regeneration (increased NCAM expression) with re-
duced necrosis.
We observed a positive effect on membrane stability in
the limb muscles of older, treated mdx mice, as ascer-tained by reduced Evans Blue dye uptake. The improve-
ment, however, was not caused by read-through of the
dystrophin stop codon mutation.5 Increased membrane
stability in response to calcium blockade was also ob-
served after blocking the L-type voltage-dependent cal-
cium channels,6 indicating that the down-regulation of
DGC proteins normally observed in DMD occurs via cal-
cium-dependent proteolytic activity. This is consistent
with the decrease in DGC proteins found in other types of
muscle wasting not related to DGC protein expression,
such as cancer.57 Our results, together with previous
data,6 therefore demonstrate that drugs capable of
blocking Ca2 uptake are directly associated with stabi-
lization of -dystroglycan. We noted that increased
-dystroglycan did not protect TA muscles after treat-
ment with verapamil and diltiazem,6 suggesting either
that the mechanism of action for streptomycin is different
from the L-type calcium channels blockers or that resto-
ration of -dystroglycan expression alone is not sufficient
to stabilize the membrane. Aminoglycoside antibiotics
can, however, displace Ca2 from biomembranes and
have a high affinity for phospholipids,58 suggesting that
they may have an ability to intercalate into the fragile
membranes of mdx muscle and stabilize them in this
manner.
Most DMD patients develop cardiomyopathy charac-
terized by left ventricular involvement, which is believed
to be directly responsible for 20% of deaths.59 Older mdx
mice present with left ventricular dilated cardiomyopathy
and fibrosis, thus mimicking DMD-associated cardiomy-
opathy.48 In the present study, we detected a trend to-
ward increased heart fibrosis in short-term treated dys-
trophic mice, which became significant with long-term
treatment. The increased fibrosis was accompanied by
substantial necrosis, suggesting a worsening of heart pa-
thology in the treated mdx mice. Functionally, dystrophic
control mice presented with a compensated cardiomyopa-
thy, similar to previous studies,47,48,60 and this was not
changed with treatment. We observed an increased left
ventricular mass in both treated and untreated mdx mice, in
agreement with previous studies.47,47,60
Calcium influx in dystrophic cardiomyocytes occurs
via several pathways, including the stretch-activated
channels, short-lived microruptures, and the Na-Ca2
exchanger.61 Calcium influx after stretch appears to de-
pend on Na permeability and thus seems to be a sec-
ondary event.62 It has been suggested that, in old mdx
hearts, increased activity and/or expression of TRPC1
might account for the increased calcium influx through
stretch-activated channels.63 However, considering the
report showing that TRPC1 does not constitute a mech-
anosensitive channel in skeletal muscle,54 lack of im-
provement in cardiac pathology after streptomycin treat-
ment could be caused by other adverse effects of
streptomycin on the heart. Specifically, it has been shown
that streptomycin affects heart cell viability in vitro.64;
thus, streptomycin could induce cardiotoxicity and this, in
combination with mitochondrial dysfunction, could ex-
plain the lack of improvement observed in the hearts.
This study demonstrates opposite effects of strepto-
mycin treatment on different tissues. Blocking calcium
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rection of the membrane fragility defect, microtears, and
nonspecific calcium uptake; eventually, necrosis, degen-
eration, and end-stage fibrosis will occur. This protection
may be more pronounced in limb muscles, compared
with diaphragm and heart, simply due to differences in
physical activity. There are two possible scenarios to
consider. First, the drug might simply reduce daily activ-
ity of the mice. This could relate to their behavior or to the
mice feeling sick.65 This is important, because reduced
or altered movements would directly reduce activity-in-
duced necrosis of mdx mice. Therefore, introducing me-
chanical stress (eg, using forced tread-mill running) and
hence inducing necrosis of the muscle might counter the
early improvement observed. We did not notice any ob-
vious behavioral changes, and the mice appeared to be
active and well-groomed, but this possibility should be
tested using specific behavior studies and exercise reg-
imens. Second, the relative activity level in limb muscle
versus diaphragm and heart may in part explain differ-
ential effects of the drug. Physical activity level of the
mice is more relevant for limb muscle than for heart and
diaphragm, as the latter are in constant motion through-
out life and undergo the same level of stress in both
control and treated mice. Based on the present findings,
systemic calcium channel blockade may not be a useful
therapeutic strategy for DMD, as it may result in an ag-
gravation of heart pathology. Calcium accumulation and
structural disturbances before clinical onset in DMD/mdx
needs careful consideration in designing future preclini-
cal drug trials in the mdx mouse, because the type of
muscle changes present at the start of intervention might
influence the outcome considerably.
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